- Home
- BGLC vs INAB Comparison
BGLC vs INAB Comparison
Compare BGLC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- INAB
- Stock Information
- Founded
- BGLC 2017
- INAB 2016
- Country
- BGLC Malaysia
- INAB United States
- Employees
- BGLC N/A
- INAB N/A
- Industry
- BGLC Medical Specialities
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- INAB Health Care
- Exchange
- BGLC Nasdaq
- INAB Nasdaq
- Market Cap
- BGLC 10.4M
- INAB 9.1M
- IPO Year
- BGLC N/A
- INAB 2021
- Fundamental
- Price
- BGLC $5.58
- INAB $2.04
- Analyst Decision
- BGLC
- INAB Strong Buy
- Analyst Count
- BGLC 0
- INAB 2
- Target Price
- BGLC N/A
- INAB $108.00
- AVG Volume (30 Days)
- BGLC 176.1K
- INAB 45.9K
- Earning Date
- BGLC 11-14-2025
- INAB 11-11-2025
- Dividend Yield
- BGLC N/A
- INAB N/A
- EPS Growth
- BGLC N/A
- INAB N/A
- EPS
- BGLC N/A
- INAB N/A
- Revenue
- BGLC $9,551,559.00
- INAB N/A
- Revenue This Year
- BGLC N/A
- INAB N/A
- Revenue Next Year
- BGLC N/A
- INAB N/A
- P/E Ratio
- BGLC N/A
- INAB N/A
- Revenue Growth
- BGLC 4.01
- INAB N/A
- 52 Week Low
- BGLC $2.01
- INAB $1.91
- 52 Week High
- BGLC $15.60
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- BGLC 53.85
- INAB 42.11
- Support Level
- BGLC $4.20
- INAB $1.98
- Resistance Level
- BGLC $6.00
- INAB $2.20
- Average True Range (ATR)
- BGLC 0.33
- INAB 0.11
- MACD
- BGLC 0.04
- INAB -0.01
- Stochastic Oscillator
- BGLC 76.76
- INAB 34.83
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.